Lenalidomide induces remission and mixed quantitative chimerism fluctuations in refractory and relapsed myeloid malignancy with del (5)

Leuk Res. 2010 Nov;34(11):e302-3. doi: 10.1016/j.leukres.2010.06.019. Epub 2010 Jul 22.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adult
  • Antineoplastic Agents / therapeutic use
  • Chimerism
  • Chromosome Deletion
  • Humans
  • Lenalidomide
  • Male
  • Myelodysplastic Syndromes / drug therapy*
  • Myelodysplastic Syndromes / genetics
  • Remission Induction / methods
  • Salvage Therapy / methods
  • Sequence Deletion
  • Thalidomide / analogs & derivatives*
  • Thalidomide / therapeutic use

Substances

  • Antineoplastic Agents
  • Thalidomide
  • Lenalidomide